CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 801–900 of 1,000
Kountz, D. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1313074 · Cited by 2
“[57] It has also been postulated that a shift in myocardial and renal metabolic substrate from fat and glucose oxidation toward the utilization of a more efficient fuel source, such as ketone bodies, may result in improved myocardial and renal efficiency.[58, 59]”
BackgroundShahady, E. J., & Leahy, J. L. (2018) · Clinical Diabetes · doi:10.2337/cd18-0064 · Cited by 4
Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires
Bauduceau, B., & Bordier, L. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30390-5 · Cited by 2
Cardiovascularis biztonságossági vizsgálatok 2-es típusú diabetesben – az első 10 év tapasztalatai
Jermendy, G. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.14 · Cited by 2
Role of Sodium-Glucose Co-transporters on Cardiac Function in Metabolic Syndrome Mammalians
Turan, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-47336-5_7 · Cited by 2
A nátrium-glükóz-kotranszporter-2-gátlók a diabetes mellitus kezelésén túl
Szekeres, Z. J., Stolcz, T., & Szabados, E. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.5.372 · Cited by 2
Großmann, S., Hoffmann, U., & Girlich, C. (2021) · Der Internist · doi:10.1007/s00108-020-00930-w · Cited by 2
Martinka, E., Uličiansky, V., Mokáň, M., Tkáč, I., Galajda, P., Dókušová, S., & Schroner, Z. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.059 · Cited by 2
FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
Fan, Z.-G., Ji, M.-Y., Xu, Y. Y., Wang, W.-X., Lu, J., & Ma, G. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2404123 · Cited by 2
“Thus, both the decrease in the number of contractile units and the damaged mitochondrial bioenergetic capacity in residual cardiomyocytes after myocardial injuries are directly linked with the progression of HF [18,19].”
BackgroundAz SGLT2-gátlók lehetséges hatásai a kardiovaszkuláris megbetegedésekben
Kosztin, A. (2023) · Cardiologia Hungarica · doi:10.26430/chungarica.2023.53.4.360 · Cited by 2
Jordan, J., El‐Armouche, A., Hanefeld, M., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Diabetes Care · doi:10.2337/dc16-1588 · Cited by 2
Thapa, S. S., Lal, A., Ömer, A., & Trivedi, N. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.021 · Cited by 2
Lazar, H. L. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.03.005 · Cited by 2
O’Sullivan, J., Koay, Y. C., Cao, Y., Bai, A. Y., Lal, S., Lusis, A. J., Kaye, D. M., & Larance, M. (2021) · Research Square · doi:10.21203/rs.3.rs-607376/v1 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
Proposed mechanisms of systemic cardiovascular action of gliflosins
Zverev, Y. F., & Rykunova, A. Y. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1915-22 · Cited by 1
Хасанов, Н. Р. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4807 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
La insuficiencia cardíaca crónica propicia la aparición de diabetes mellitus tipo 2
Márquez-Salom, G. A., Márquez-Zuccardi, Á., & Márquez-Fernández, A. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.22000107 · Cited by 1
“…el trabajo miocárdico y es así como el corazón provoca un estado de resistencia a la insulina en el TAV para conseguir áci-dos grasos, cetonas y, en el mejor de los casos, preferen-cialmente, hidroxibutirato, lo cual se manifiesta con mayor expresión miocárdica de acetil CoA carboxilasa 4-6 .”
BackgroundAkamine, M. A. V., Soares, B. M. A. F., Telles, J. P. M., de Assis, A. C. R., Rodriguez, G. N. V., Soares, P. R., Chalela, W. A., & Scudeler, T. L. (2024) · Pharmaceuticals · doi:10.3390/ph17070920 · Cited by 1
Croteau, É., Richard, G. M., Prud’Homme, P., Rousseau, É., Cunnane, S. C., Dumulon‐Perreault, V., Sarrhini, O., Phoenix, S., Tremblay, S., Guérin, B., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01215-9 · Cited by 1
“The concept that the failing heart has increased ketone body oxidation is generally accepted, but the exact role of ketones and the impact of pharmacological interventions on this specific metabolism remain to be elucidated [48].”
Akkawi, M., Upreti, P., Damlakhy, A., Kidess, G. G., Hamza, M., Rajak, K., Turkmani, M. M., Harmouch, K. M., Bahar, Y., & Alraies, M. C. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.04.013 · Cited by 1
Alazrag, W., Lambrakis, K., Pasquale, C. G. D., Joseph, M. X., Hecker, T., French, J. K., & Chew, D. P. (2025) · Next research. · doi:10.1016/j.nexres.2025.101033 · Cited by 1
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly
Bianchettin, R. G., Poirier, P., López-Jiménez, F. A., Lavie, C. J., & Piché, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00777-2 · Cited by 1
Empagliflozin attenuates inflammation and myocardial injury in a murine model of sepsis
Al-killidar, S. M., & Muhammad-Baqir, B. M. (2025) · Babcock University Medical Journal · doi:10.38029/babcockuniv.med.j..v8i2.1021 · Cited by 1
“Its cardioprotective effects are mediated through multiple mechanisms: improved myocardial energy efficiency via ketone utilisation (14, 15), reduced reactive oxygen species (ROS) production (16), decreased cardiac fibrosis (16, 17), and modulation of the sodium-hydrogen exchanger in the heart and…”
Badr, A., Suppah, M., Awad, K., Abbas, M. T., Abdullah, H. A., Arsanjani, R., Ayoub, C., & Alsidawi, S. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.014 · Cited by 1
Meco, M., Agosteo, E., Zulli, P., Nisi, F., & Giustiniano, E. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16030156 · Cited by 3
“This “substrate shift” has been proposed as a contributor to cardiovascular benefit, encapsulated by the “thrifty substrate” hypothesis, where mildly increased circulating ketones might support myocardial energetics under chronic stress conditions [4].”
Epelde, F. (2026) · Current Cardiology Reviews · doi:10.2174/011573403x435290251201095734 · Cited by 1
Wang, T., Wang, T., & Zhang, R. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447498 · Cited by 1
“Concurrently, these agents enhance myocardial ketone body utilization as an efficient energy substrate, 45 attenuate the production of reactive oxygen species, and bolster cellular resilience against oxidative stress.”
Tomar, V., Çetin, T. E., Demirezen, A., Akçay, Ö. F., Derici, Ü., Güz, G., & Helvacı, Ö. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02200-5 · Cited by 1
“Experimental studies indicate that SGLT2 inhibitor–related elevations in β-HB are largely driven by increased hepatic ketone production rather than impaired renal elimination [4].”
InfluentialChallenges in treating with SGLT2 inhibitors in daily practice
Niklas, A. A., Wierzowiecka, M., Krasińska, B., Kadziszewski, R. W., Zawiejska, A., Dzida, G. J., Wysocki, A., Adamczak, M., & Stompor, T. (2026) · Arterial Hypertension · doi:10.5603/ah.106312 · Cited by 2
Naik, V., Darandale, A., & Pal, P. (2026) · Cardiovascular Disease Prevention and Control · doi:10.64229/v3v43h95 · Cited by 1
“Although this is believed to increase myocardial energy efficiency and reduce oxidative stress, this process is still under investigation and has not yet been validated in a clinical environment [12].”
SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AS NEW STRATEGY OF CHRONIC HEART FAILURE MANAGEMENT
Herashchenko, A. S., & Fedorov, S. V. (2020) · Emergency Medical Service · doi:10.36740/emems202003109 · Cited by 1
The relationship between glucagon levels and cardiovascular risk in patients with type 2 diabetes
Jeong, W.-S., Moon, J., & Yoo, S. (2020) · Journal of Medicine and Life Science · doi:10.22730/jmls.2020.17.2.47 · Cited by 1
The Impact of Carbohydrate Restriction and Nutritional Ketosis on Cardiovascular Health
Lowe, D. A., Corbit, K. C., & Weiss, E. J. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_5 · Cited by 1
BAJAJ, H. S., & Zinman, B. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.08.220 · Cited by 1
Is diabetes still a state of premature cardiovascular death?
Fisher, M. (2016) · Practical Diabetes · doi:10.1002/pdi.2057 · Cited by 1
Comments on current guidelines of type 2 diabetes mellitus treatment
Martinka, E. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.042 · Cited by 1
Stratégie thérapeutique dans le traitement du diabète de type 2
Bauduceau, B., & Bordier, L. (2018) · Time to knit · doi:10.1016/s1155-1941(18)82762-7 · Cited by 1
Making sense of newer treatment options for type 2 diabetes
Lee, P. C., Hare, M. J. L., & Bach, L. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.13947 · Cited by 2
Ketone Bodies Are an Alternative Energy Source and Exert Antioxidant Effects
Hattori, Y. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0287 · Cited by 1
Left ventricular noncompaction with intractable heart failure responsive to empagliflozin
Chiba, Y., Yonezawa, K., Himeno, M., Yukino, M., Shimazu, K., Imagawa, S., Komuro, K., Kimura, N., Anzai, T., & Anzai, T. (2018) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2018.07.008 · Cited by 1
Patoulias, D. (2019) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2019.83302 · Cited by 1
Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire
Falcetta, P., Indovina, F. S., Coppelli, A., Daniele, G., & Prato, S. D. (2019) · L Endocrinologo · doi:10.1007/s40619-019-00646-6 · Cited by 1
Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2
Vergès, B. L. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30961-9 · Cited by 1
Castillo, G. A., & Morales-Villegas, E. (2020) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.12.004 · Cited by 4
Nasab, H. R., Habibi, A. H., Nikbakht, M., Rashno, M. M., & Shakerian, S. (2021) · PubMed Central · doi:10.22074/cellj.2021.6942 · Cited by 3
Polozova, E. I., Prokhorova, T. A., Khokhlova, L. N., & Sadi, A. A. (2020) · Современные проблемы науки и образования · doi:10.17513/spno.30039 · Cited by 1
Özışık, H., Çetinkalp, Ş., Candemir, A., Süner, A., & Nalbantgil, S. (2020) · Journal of Integrative Cardiology · doi:10.15761/jic.1000296 · Cited by 1
SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease
FITCHETT, D. H. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_33 · Cited by 1
el-Andari, R., Fialka, N., Kang, J. J. H., Bozso, S., Nagendran, J., & Nagendran, J. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00618-0 · Cited by 1
“Results demonstrated a significant reduction in cardiovascular death or heart failure (HF) in the empagli-flozin group [21–23].”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
“Die zugrunde liegenden Mechanismen der kardialen und renalen Protektion von Empaglif lozin sind Gegenstand umfangreicher Studien [89, 90].”
Kashiwagi, Y., Nagoshi, T., Tanaka, Y., Oi, Y., Kimura, H., Ogawa, K., Kawai, M., & Yoshimura, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-67524-6 · Cited by 2
Diabetes Care: “Lagniappe” and “Seeing Is Believing”!
Cefalu, W. T., Boulton, A. J. M., Tamborlane, W. V., Moses, R. G., LeRoith, D., Greene, E. L., Hu, F. B., Bakris, G. L., Wylie‐Rosett, J., Rosenstock, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0891 · Cited by 1
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Diabetes Care · doi:10.2337/dc16-1332 · Cited by 1
MacIsaac, R. J., & Ekinci, E. I. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.11 · Cited by 1
Prattichizzo, F. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108030 · Cited by 1
Yesilyurt, Z. E., Karaömerlioğlu, İ., Erdoğan, B. R., Ozturk, G., Michel, M. C., & Arioglu‐Inan, E. (2021) · Research Square · doi:10.21203/rs.3.rs-526255/v1 · Cited by 1
[At the heart of diabetic cardiomyopathy: Bscl2 knockout mice to investigate glucotoxicity].
Lugat, A., Joubert, M., Cariou, B., & Prieur, X. (2018) · PubMed · doi:10.1051/medsci/20183406016 · Cited by 3
Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.1536 · Cited by 26
London buses: A cardiovascular outcome trial equivalent?
Grant, P. J. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116663051
La mejoría del pronóstico cardiovascular de la diabetes mellitus tipo 2 ¿es una realidad?
Ruiz‐Hurtado, G., Vigil, L., & Ruilope, L. M. (2016) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2016.10.001
Hypertension in type 2 diabetes: impact of glucose-lowering medications
Krentz, A. J. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000100
Empagliflozyna. Wyniki badania EMPA-REG OUTCOME. Przełom w leczeniu cukrzycy typu 2?
Strojek, K., Rokicka, D., Szymborska‐Kajanek, A., & Wróbel, M. P. (2016) · Via Medica Journals
Kardiovaskuläre Aspekte der Diabetestherapie: Endlich Grund zur Freude für Kardiologen
Forst, T. M., Plum‐Mörschel, L., & Weber, M. M. (2017) · Der Internist · doi:10.1007/s00108-017-0189-0
Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes
Kim, N. H., & Kim, S. G. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.1.7
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30055-x · Cited by 1
Glycemic Control and Diabetes Macroangiopathy
Bordier, L., & Bauduceau, B. (2017) · International Journal of Medicine and Surgery · doi:10.15342/ijms.v4is.136
Perspectives on medical treatment of type 2 diabetes mellitus
Yoshioka, N. (2017) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.23.015
Verbesserung des metabolischen Stoffwechsels bei Patienten mit Typ-2-Diabetes
Birkenfeld, A. L. (2017) · Diabetes aktuell · doi:10.1055/s-0043-113676
Herzinsuffizienz und Diabetes: Therapeutische Strategien unter Berücksichtigung aktueller Studien
Rau, M., & Lehrke, M. (2017) · Der Klinikarzt · doi:10.1055/s-0043-113349
Seufert, J., Galle, J.-C., Manning, M., Schmid, V., & Lehrke, M. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-112658
Is the Renoprotective Effect of SGLT2 Inhibitors due to their Beneficial Effect on Hypomagnesemia?
Yanagawa, T. (2017) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000772
Hypertonie und Typ-2-Diabetes: zwei „üble Gesellen“
Kristian, R. E. T. T. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-0175-4
Wirkung von SGLT-2-Inhibitoren auf eine gestörte ventrikuläre Repolarisation
Jecht, M. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0279-6
“Die Ergebnisse der EMPA-REG-Studie [2] lösten eine Vielzahl von Überlegungen zu den Gründen der für alle überraschenden Ergebnisse bei der Senkung derMortalität aus [1, 3–5].”
BackgroundInfluentialDiabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift
Kelly, E. M., & Cutlip, D. E. (2018) · US Cardiology Review · doi:10.15420/usc.2017:35:1
Protective Effect of Anti-diabetic Drugs on Cardiovascular Diseases
Hirano, T. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.1029
Cho, Y., & Kang, E. S. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.1.21
Research advances in metabolism 2017
Perakakis, N., Ghaly, W., Peradze, N., Boutari, C., Batırel, S., Douglas, V. P., & Mantzoros, C. S. (2018) · Metabolism · doi:10.1016/j.metabol.2018.01.018
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., Clarine, L., & Rodríguez-Martínez, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_34
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
Jeon, J. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.81
“로의 산소 전달을 용이하게 하여 산화적 인산화(oxidative phosphorylation)에 의한 미토콘드리아에서의 에너지 생성 에 기여할 수 있다[23].”
Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients
Yu, S. H. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.4.233
“최근에 진행된 EMPA-REG OUTCOME 연구, CANVAS 연구 등 sodium-glucose cotransporter 2 (SGLT2) 억제 제의 심혈관 합병증에 대한 연구를 보면 혈당의 조절보다는 약제의 선택이 심혈관계 질환의 예방 및 악화에 영향을 줄 수 있을 것이라는 기대를 해 볼 수 있겠으며, 최근 발표된 진료지침에서 심혈관질환이 동반된 경우 우선적으로 사용 할 것을 권고하고 있다[8-10].”
Baker, H. E. (2020) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2031
Bhat, P., & Tang, W. H. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64067-1.00036-x
Sodium-glucose co-transporter-2 inhibitors
Suvarna, V. R. (2021) · Perspectives in Clinical Research · doi:10.4103/picr.picr_156_19
Gliflozin verbessert Urin-Metabolom auch bei nierengesunden Diabetikern
Fritschka, E. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3701-5
Patoulias, D., Papadopoulos, C. E., & Doumas, M. N. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.002
Cardiorenal effects of newer antidiabetic agents
Papazafiropoulou, A. K., Georgopoulos, E., & Antonopoulos, S. (2020) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1010
Rocca, J. (2021) · International Journal of Diabetes and Endocrinology · doi:10.46715/ijde2021.08.1000118
SGLT2阻害薬によるGlobal Longitudinal Strain (GLS)に対する効果の検討
一弘, 上. (2020) · 心臓 · doi:10.11281/shinzo.52.867
Connelly, K. A., Wu, X., Visram, A., Friedberg, M. K., Batchu, S. N., Yerra, V. G., Thai, K., Nghiem, L., Zhang, Y., Kabir, G., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-966875/v1
Contribution of Ketone Oxidation on Energy Production in the Failing Heart
Pherwani, S. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-2dz6-3t18
Avaliação da influência do vinho tinto sobre a microbiota intestinal e N-óxido de trimetilamina
Haas, E. A. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-06122021-125446
Nashawi, M., Ahmed, M. S., Ahmad, M. I., Issa, O., & Abualfoul, M. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1139
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00765-5
Connelly, K. A., Wu, X., Visram, A., Friedberg, M. K., Batchu, S. N., Yerra, V. G., Thai, K., Nghiem, L., Zhang, Y., Kabir, G., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-966875/v2
Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy
Bell, R. (2019) · Heart and Metabolism · doi:10.31887/hm.2019.80/rbell
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.